3-(2,2,2-trimethylhydrazine)propionate has been researched along with Coronary Disease in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vatseba, MO | 1 |
| Ermolenko, AA; Statsenko, ME; Turkina, SV | 1 |
| Karpov, ES; Lyamina, NP; Razborov, IB | 1 |
| Lobzeva, VI; Novikova, EB; Savchuk, VI; Seregin, EO; Zhemerikina, EV | 1 |
| Golokolenova, GM; Ol'binskaia, LI | 1 |
| Cherkasova, NA; Giliarovskiĭ, AK; Mikhaĭlov, AA; Simonov, VI; Zhelnov, VV | 1 |
| Artiukh, VP; Denisenko, GT; Sakharchuk, II; Sisetskiĭ, AP; Starodub, NF | 1 |
| Meĭrena, DV; Shutenko, ZhV; Simkhovich, BZ; Stivrinia, MI; Vitolinia, RO | 1 |
1 review(s) available for 3-(2,2,2-trimethylhydrazine)propionate and Coronary Disease
| Article | Year |
|---|---|
[Unsolved problems of cytoprotective therapy in patients with coronary heart disease].
Topics: Cardiotonic Agents; Cardiovascular Agents; Coronary Disease; Humans; Methylhydrazines; Trimetazidine | 2015 |
2 trial(s) available for 3-(2,2,2-trimethylhydrazine)propionate and Coronary Disease
| Article | Year |
|---|---|
[Experimental and clinical studies of coronary circulation after administration of mildronate].
Topics: Adult; Aged; Animals; Coronary Circulation; Coronary Disease; Dogs; Drug Evaluation, Preclinical; Humans; Male; Methylhydrazines; Middle Aged; Vasodilator Agents | 1991 |
[Use of mindronate in cardiac insufficiency in patients with ischemic heart disease].
Topics: Adult; Aged; Cardiomyopathy, Dilated; Clinical Trials as Topic; Coronary Disease; Female; Hemodynamics; Humans; Male; Methylhydrazines; Middle Aged; Vasodilator Agents | 1990 |
5 other study(ies) available for 3-(2,2,2-trimethylhydrazine)propionate and Coronary Disease
| Article | Year |
|---|---|
[Endothelial dysfunction as a marker of vascular aging syndrome on the background of hypertension, coronary heart disease, gout and obesity].
Topics: Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Cardiovascular Agents; Carotid Arteries; Coronary Disease; Elasticity; Endothelium, Vascular; Female; Gout; Humans; Hypertension; Losartan; Male; Methylhydrazines; Middle Aged; Obesity; Severity of Illness Index; Tunica Intima; Tunica Media; Vascular Stiffness | 2013 |
[Clinical and Economic Aspects of Meldonium as Part of Physical Rehabilitation Programs in Patients With Coronary Heart Disease After Percutaneous Coronary Interventions].
Topics: Cardiovascular Agents; Coronary Disease; Exercise Test; Exercise Tolerance; Female; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Treatment Outcome | 2016 |
[Effects of mildronate (quaterin) on hemodynamics in spontaneous and artificial heart rhythm in patients with ischemic heart disease].
Topics: Adult; Aged; Aged, 80 and over; Cardiac Pacing, Artificial; Cardiovascular Agents; Coronary Disease; Electrocardiography; Female; Heart Rate; Hemodynamics; Humans; Male; Methylhydrazines; Middle Aged | 1990 |
[Effects of mildronate on hemoglobin ligand spectrum in patients with ischemic heart disease complicated by coronary insufficiency].
Topics: Aged; Cardiovascular Agents; Coronary Disease; Heart Failure; Hemoglobins; Humans; Ligands; Male; Methemoglobin; Methylhydrazines; Middle Aged; Oxyhemoglobins | 1990 |
[Prevention of ischemic myocardial damage by reducing the intracellular free carnitine level].
Topics: Animals; Carnitine; Cell Membrane; Coronary Disease; gamma-Butyrobetaine Dioxygenase; Male; Methylhydrazines; Mixed Function Oxygenases; Myocardium; Rabbits; Rats | 1987 |